AAAAAA

   
Results: 1-15 |
Results: 15
Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes
Authors: Stoll, SW Kansra, S Peshick, S Fry, DW Leopold, WR Wiesen, JF Sibilia, M Zhang, T Werb, Z Derynck, R Wagner, EF Elder, JT
Citation: Sw. Stoll et al., Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes, NEOPLASIA, 3(4), 2001, pp. 339-350
Anticancer therapy targeting the ErbB family of receptor tyrosine kinases
Authors: Slichenmyer, WJ Fry, DW
Citation: Wj. Slichenmyer et Dw. Fry, Anticancer therapy targeting the ErbB family of receptor tyrosine kinases, SEMIN ONCOL, 28(5), 2001, pp. 67-79
Cl-1033, a pan-erbB tyrosine kinase inhibitor
Authors: Slichenmyer, WJ Elliott, WL Fry, DW
Citation: Wj. Slichenmyer et al., Cl-1033, a pan-erbB tyrosine kinase inhibitor, SEMIN ONCOL, 28(5), 2001, pp. 80-85
Tyrosine kinase inhibitors. 18. 6-substituted 4-anilinoquinazolines and 4-anilinopyrido [3,4-d]pyrimidines as soluble, irreversible inhibitors of theepidermal growth factor receptor
Authors: Smaill, JB Showalter, HDH Zhou, HR Bridges, AJ McNamara, DJ Fry, DW Nelson, JM Sherwood, V Vincent, PW Roberts, BJ Elliott, WL Denny, WA
Citation: Jb. Smaill et al., Tyrosine kinase inhibitors. 18. 6-substituted 4-anilinoquinazolines and 4-anilinopyrido [3,4-d]pyrimidines as soluble, irreversible inhibitors of theepidermal growth factor receptor, J MED CHEM, 44(3), 2001, pp. 429-440
Cell cycle and biochemical effects of PD 0183812 - a potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6
Authors: Fry, DW Bedford, DC Harvey, PH Fritsch, A Keller, PR Wu, ZP Dobrusin, E Leopold, WR Fattaey, A Garrett, MD
Citation: Dw. Fry et al., Cell cycle and biochemical effects of PD 0183812 - a potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6, J BIOL CHEM, 276(20), 2001, pp. 16617-16623
Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition
Authors: Nelson, JM Fry, DW
Citation: Jm. Nelson et Dw. Fry, Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition, J BIOL CHEM, 276(18), 2001, pp. 14842-14847
Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts
Authors: Vincent, PW Bridges, AJ Dykes, DJ Fry, DW Leopold, WR Patmore, SJ Roberts, BJ Rose, S Sherwood, V Zhou, HR Elliott, WL
Citation: Pw. Vincent et al., Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts, CANC CHEMOT, 45(3), 2000, pp. 231-238
Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer
Authors: Fry, DW
Citation: Dw. Fry, Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer, ANTI-CAN DR, 15(1), 2000, pp. 3-16
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]-pyrimidine-6-acrylamides bearing additional solubilizing functions(vol 43, pg 1380, 2000)
Authors: Smaill, JB Rewcastle, GW Bridges, AJ Zhou, HR Showalter, HDH Fry, DW Nelson, JM Sherwood, V Elliott, WL Vincent, PW DeJohn, DE Loo, JA Greis, KD Chan, OH Reyner, EL Lipka, E Denny, WA
Citation: Jb. Smaill et al., Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]-pyrimidine-6-acrylamides bearing additional solubilizing functions(vol 43, pg 1380, 2000), J MED CHEM, 43(16), 2000, pp. 3199-3199
Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in Apc(Min) mice but induces duodenal injury
Authors: Ritland, SR Gendler, SJ Burgart, LJ Fry, DW Nelson, JM Bridges, AJ Andress, L Karnes, WE
Citation: Sr. Ritland et al., Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in Apc(Min) mice but induces duodenal injury, CANCER RES, 60(17), 2000, pp. 4678-4681
Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2
Authors: Owen, JD Ruest, PJ Fry, DW Hanks, SK
Citation: Jd. Owen et al., Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2, MOL CELL B, 19(7), 1999, pp. 4806-4818
Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors
Authors: Sun, Y Fry, DW Vincent, P Nelson, JM Elliott, W Leopold, WR
Citation: Y. Sun et al., Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors, ANTICANC R, 19(2A), 1999, pp. 919-924
Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
Authors: Fry, DW
Citation: Dw. Fry, Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors, PHARM THERA, 82(2-3), 1999, pp. 207-218
Tyrosine kinase inhibitors. 16. 6,5,6-tricyclic benzothieno [3,2-d]pyrimidines and pyrimido[5,4-b]- and -[4,5-b]indoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase
Authors: Showalter, HDH Bridges, AJ Zhou, HR Sercel, AD McMichael, A Fry, DW
Citation: Hdh. Showalter et al., Tyrosine kinase inhibitors. 16. 6,5,6-tricyclic benzothieno [3,2-d]pyrimidines and pyrimido[5,4-b]- and -[4,5-b]indoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase, J MED CHEM, 42(26), 1999, pp. 5464-5474
Tyrosine kinase inhibitors. 15. 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[d] pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor
Authors: Smaill, JB Palmer, BD Rewcastle, GW Denny, WA McNamara, DJ Dobrusin, EM Bridges, AJ Zhou, HR Showalter, HDH Winters, RT Leopold, WR Fry, DW Nelson, JM Slintak, V Elliot, WL Roberts, BJ Vincent, PW Patmore, SJ
Citation: Jb. Smaill et al., Tyrosine kinase inhibitors. 15. 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[d] pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor, J MED CHEM, 42(10), 1999, pp. 1803-1815
Risultati: 1-15 |